Title |
Acquired hypofibrinogenemia: current perspectives
|
---|---|
Published in |
Journal of Blood Medicine, September 2016
|
DOI | 10.2147/jbm.s90693 |
Pubmed ID | |
Authors |
Martin W Besser, Stephen G MacDonald |
Abstract |
Acquired hypofibrinogenemia is most frequently caused by hemodilution and consumption of clotting factors. The aggressive replacement of fibrinogen has become one of the core principles of modern management of massive hemorrhage. The best method for determining the patient's fibrinogen level remains controversial, and particularly in acquired dysfibrinogenemia, could have major therapeutic implications depending on which quantification method is chosen. This review introduces the available laboratory and point-of-care methods and discusses the relative advantages and limitations. It also discusses current strategies for the correction of hypofibrinogenemia. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United Kingdom | 1 | 25% |
United States | 1 | 25% |
Australia | 1 | 25% |
Unknown | 1 | 25% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Practitioners (doctors, other healthcare professionals) | 3 | 75% |
Members of the public | 1 | 25% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 79 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Bachelor | 15 | 19% |
Other | 12 | 15% |
Student > Ph. D. Student | 9 | 11% |
Student > Master | 7 | 9% |
Researcher | 6 | 8% |
Other | 13 | 16% |
Unknown | 17 | 22% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 30 | 38% |
Biochemistry, Genetics and Molecular Biology | 11 | 14% |
Pharmacology, Toxicology and Pharmaceutical Science | 6 | 8% |
Agricultural and Biological Sciences | 6 | 8% |
Chemistry | 2 | 3% |
Other | 7 | 9% |
Unknown | 17 | 22% |